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Abstract
Background: Dementia due to Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB) are the two most
common neurodegenerative causes of dementia. They commonly occur together, especially in older people, but
clinical identification of these diseases in dementia is difficult in such circumstances. We therefore conducted a
study using cases with both comprehensive prospective clinical assessments and complete neuropathological
examination to determine if it is possible to identify such mixed cases clinically and to determine features which
may identify DLB in the presence of AD dementia.
Methods: At Newcastle Brain Bank we identified subjects who had a clinical diagnosis of dementia and who also
had autopsy diagnoses of pure AD, pure DLB, or mixed AD+DLB. All subjects had undergone prospective longitudinal
clinical assessments. Mixed AD+DLB patients met neuropathological criteria for both DLB (limbic/neocortical Lewy
body disease) and AD (Braak stage V/VI and CERAD B/C). The records of these subjects were carefully reviewed by two
specialists in old-age psychiatry blind to autopsy findings to determine baseline and final clinical diagnoses based on
these detailed records. The presence of characteristic Lewy body symptoms and other clinical information was also
recorded.
Results: Of 59 subjects included, 19 were AD, 18 DLB, and 22 mixed AD+DLB. At baseline no subjects were correctly
identified as having mixed AD+DLB and by final diagnosis only 23% were identified. The only symptom which helped
in identifying the presence of Lewy body disease in the context of a mixed AD+DLB dementia was complex visual
hallucinations.
Conclusions: Whilst the identification of DLB in the context of a dementia with an AD pattern is difficult, the
emergence of complex visual hallucinations in the context of such a degenerative dementia suggests the
presence of Lewy body disease and should encourage a careful assessment. Biomarkers appear likely to be
necessary to help improve identification of different disease subtypes underlying dementia.
Keywords: Dementia, DLB, AD, Neuropathology, Mixed pathology
* Correspondence: alan.thomas@ncl.ac.uk
Institute of Neuroscience, Newcastle University, Biomedical Research Building,
Campus for Ageing and Vitality, Newcastle upon Tyne NE4 5PL, UK
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Thomas et al. Alzheimer's Research & Therapy  (2018) 10:27 
https://doi.org/10.1186/s13195-018-0356-0
Background
The presence of Lewy bodies (LBs) in the cortex of people
with dementia was first reported by Okazaki et al. in two
patients in 1961 [1] but it was the larger case series from
Kosaka et al. about 20 years later [2] that established the
link between dementia and cortical LB disease. Subsequent
studies in the 1980s and 1990s led to the wider recognition
of dementia with Lewy bodies (DLB) as a clinicopathologi-
cal entity distinct from Alzheimer’s disease (AD) and fur-
ther led to the formulation of the international consensus
diagnostic criteria for DLB [3, 4]. These diagnostic criteria
have a high specificity, but their sensitivity is considerably
lower despite improvements in clinical diagnostics with the
incorporation of REM sleep behaviour disorder (RBD) and
FP-CIT imaging [5, 6]. Hence, many DLB patients are clin-
ically misdiagnosed as AD and therefore not provided with
appropriate treatment.
A few previous clinicopathological studies have endea-
voured to determine a clinical correlate that that will
help identify the clinical manifestation of DLB in the
presence of co-morbid AD [7–10]. Whilst suggesting
that visuospatial dysfunction or visual hallucinations
may help identify DLB in the context of an AD-type de-
mentia, these studies have had low numbers (e.g. [8]),
limited clinical assessments, and did not fulfil the full
complement of consensus criteria required for definite
AD and DLB [4, 11–14].
It therefore remains unclear whether it is possible for cli-
nicians to detect the presence of DLB by clinical assessment
in the context of a dementia that is also due to AD, and if so
what features might enable such identification. The clinical
importance of identifying DLB to avoid inappropriate and
dangerous use of antipsychotics is now well recognised [15],
but missing people who develop DLB in the context of AD
dementia puts people at risk of such adverse reactions. Fur-
thermore, the prospect of disease-modifying drug therapies
has encouraged the move towards identification of specific
diseases and stratification of dementia subgroups by aeti-
ology. The development of any successful disease-modifying
treatments for amyloid, tau, or synuclein pathology would
make the identification of co-morbidity highly important to
facilitate stratification for treatment optimisation, especially
as it has been demonstrated that co-morbid tau pathology
confers a worse prognosis in patients with DLB [16]. We
therefore investigated firstly whether specialist old-age psy-
chiatrists could distinguish autopsy-confirmed mixed AD
+DLB cases from those clinically and neuropathologically
diagnosed as pure AD or pure DLB, and secondly what clin-
ical features might enable such a distinction to be made.
Methods
Study cohort
We searched the Newcastle Brain Tissue Resource (NBTR)
and identified 22 cases that fulfilled neuropathological
criteria for both full-blown AD and DLB, i.e. mixed AD
+DLB. In addition, 19 cases were included that fulfilled
neuropathological criteria for pure AD and 18 for pure
DLB. Demographic data of our study cohort are displayed
in Table 1. Cases came to autopsy between 2005 and 2015
and the AD subjects made up 20% of those in our brain
bank; the DLB subjects made up 60%. All cases had longi-
tudinal clinical data available that were retrieved from rele-
vant research records and all secondary care health service
records, detailing assessments, investigations, and manage-
ment in memory/dementia services and all other health
services (see below). All these clinical records were
assessed by two specialists in old-age psychiatry (FMB and
MS) who were blind to the autopsy findings.
Clinical assignment of diagnoses
Assessment involved the specialists carefully reading all
health service and research records, noting key symp-
toms, and summarising the data. Following this, each
specialist then assigned baseline and final clinical diag-
noses to all patients whilst blind to autopsy findings
based on this information. Baseline diagnosis was that at
the first recorded clinical assessment and final diagnosis
was that made at the last time before death when all
relevant clinical information was available (service re-
cords on terminal illness did not usually provide infor-
mation relevant to making or altering a dementia
subtype diagnosis). Where there was disagreement about
the diagnosis (which occurred in 11 cases at baseline
and 14 at final diagnosis, overall 21% of cases) a third in-
dependent expert in dementia diagnosis (AT) reviewed
the records to assign a consensus final clinical diagnosis.
Pure (p)AD and pDLB cases were diagnosed by applying
standard diagnostic criteria (NIA-AA (2011) [17] and
Consensus DLB Third report (2005) [3]). At baseline,
the presence of any supportive LB features, e.g. delusions
or depression, in a case (without core LB symptoms)
raised the possibility of it being mixed. After baseline,
the emergence of core LB symptoms or supportive
symptoms in someone with gradual cognitive decline
and worsening functional impairment (i.e. AD-like de-
cline) raised the possibility of this case being mixed.
To ensure there was consistency in the identification
of relevant clinical data, each specialist independently
reviewed records on six patients who had been reviewed
by the other specialist. Their records were compared
and there was good agreement on the data obtained.
Neuropathological diagnosis
At autopsy the right hemisphere, brainstem, and cerebel-
lum were immersed and fixed in 4% buffered aqueous
formalin for 4–6 weeks. Brain regions including frontal,
temporal, parietal and occipital cortices, cingulate and
hippocampus, striatum (including both caudate nucleus
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and putamen), amygdala, midbrain, and locus coeruleus
were embedded into paraffin wax, sectioned at 6 μm and
mounted on 4% 3-aminopropyltriethoxysilane slides.
Immunostaining with monoclonal antibodies against
hyper-phosphorylated tau (HP-τ; AT8, dilution 1:4000,
Innogenetics, Ghent, Belgium), Aβ (4G8, dilution
1:15,000, 4G8, Signet Labs, Dedham, MA, USA), and α-
synuclein (α-syn, dilution 1:200, Chemicon, Hofheim,
Germany) was carried out. Prior to this, slides were
microwaved for antigen retrieval in 0.01Mol L-1 citrate
buffer for 10 min (AT8), pressure cooked in 0.01Mol L-1
EDTA for 90 s (α-syn), or immersed for 1 h in Formic
acid (4G8). Immunopositivity was assessed using a
MENAPATH HRP polymer detection kit (Menarini
diagnostics, Berkshire, UK) with chromagen 3,3 diami-
nobezidine (DAB) and counterstained with haematoxy-
lin. Tissue was finally dehydrated through an alcohol
series, cleared, and mounted using DPX (CellPath,
Powys, UK).
Pathological diagnoses were assigned using inter-
nationally accepted criteria by a senior neuropathologist
(JA). This included neurofibrillary tangle (NFT) Braak
stages [11, 18], CERAD scores [13], NIA-RI criteria,
where Thal amyloid β phases were available NIA-AA cri-
teria [12, 14, 19], and the Newcastle McKeith criteria for
DLB [3, 4]. Subjects were divided into three groups, pure
AD (pAD), pure DLB (pDLB), and mixed AD+DLB, the
latter being assigned when the neuropathological criteria
was fulfilled for both AD and DLB [20]. Subjects
assigned to the pAD and pDLB groups displayed only
minimal concomitant pathology associated with other
neurodegenerative diseases or cerebrovascular disease.
Statistical analysis
The Statistical Package for Social Sciences software
(SPSS version 23) was used for statistical evaluation. For
group comparisons, chi-squared tests were used for cat-
egorical variables and for continuous variables we tested
for normality of distribution and analysis of variance
(ANOVA) and t tests or Mann Whitney tests were used.
Clinician diagnostic accuracy (sensitivity, specificity, and
overall accuracy) was calculated from standard 2 × 2
frequency tables and 95% confidence intervals for these
calculated using Minitab (version 16.1). Inter-rater reli-
ability was assessed using the kappa coefficient.
The tissue and associated data used in this study were
from the NBTR and used in accordance with ethical
approvals for NBTR.
Results
General observations
Study demographics are displayed in Table 1. Patients
with a neuropathological diagnosis of mixed AD+DLB
and those diagnosed as pDLB were significantly younger
Table 1 Characteristics of subjects by final neuropathological
diagnosis
AD DLB Mixed AD+DLB
N = 19 N = 18 N = 22
Age at baseline
(years)
76.8
(9.3)
71.0
(6.1)
70.5
(9.0)
F = (2,56)
3.4, P = 0.04
DLB vs AD,
P = 0.03
DLB vs
mixed, P = 0.87
AD vs mixed,
P = 0.04
Age at death
(years)
82.7
(9.4)
76.9
(5.3)
78.2
(8.8)
F = (2,56) 2.6,
P = 0.08
DLB vs AD,
P = 0.03
DLB vs mixed,
P = 0.58
AD vs mixed,
P = 0.16
Gender
(male:female)
13:6 14:4 16:6 X = 0.41,
df = 2,
P = 0.82
Interval between
baseline and death
(years)
5.8
(2.5)
5.9
(1.9)
7.8
(2.6)
F = (2,56) 4.5,
P = 0.015
DLB vs AD,
P = 0.83
DLB vs mixed,
P = 0.02
AD vs mixed,
P = 0.02
Baseline MMSE 18.0
(7.5)
25.3
(2.7)
22.0
(3.9)
F = (2,52) 8.5,
P = 0.001
DLB vs AD,
P = 0.001
DLB vs mixed,
P = 0.01
AD vs mixed,
P = 0.04
Final MMSE 5.9
(7.8)
12.8
(6.9)
6.8
(9.4)
F = (2,53) 3.6,
P = 0.04
DLB vs AD,
P = 0.01
DLB vs mixed,
P = 0.04
AD vs mixed,
P = 0.75
Interval between
last assessment
and death
(months)
20.9
(13.8)
25.4
(17.1)
35.9
(28.7)
F = (2,51) 2.5,
P = 0.09
DLB vs AD,
P = 0.40
DLB vs mixed,
P = 0.19
AD vs mixed,
P = 0.05
AD Alzheimer’s disease, DLB dementia with Lewy bodies, MMSE Mini-
Mental State Examination
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than pAD patients at baseline clinical assessment (P <
0.05). Patients with a neuropathological diagnosis of
mixed AD+DLB had a significantly longer time interval
between baseline clinical assessment and death com-
pared to both pAD and pDLB (P < 0.05). At baseline,
the Mini-Mental State Examination (MMSE) score in
pAD cases was significantly lower than in the mixed AD
+DLB group (P < 0.05), while such a difference was not
observed at final assessment (P = 0.75). Although not
statistically significant, the interval between last clinical
assessment and death was longer in the mixed AD
+DLB group compared to the pAD (P = 0.05) and
pDLB (P = 0.19) groups. Controlling for such differ-
ences did not affect any of the findings below.
Baseline clinical diagnoses
At baseline none of the subjects who had mixed AD
+DLB pathology were diagnosed as such. Each had been
given a specific subtype diagnosis. Thus, sensitivity of
clinical diagnosis for neuropathologically mixed AD
+DLB at baseline was 0% and specificity was 100%, giv-
ing an overall diagnostic accuracy of 62.7%. For pAD the
sensitivity was 74% (95% confidence interval, 49 to 91),
the specificity was 63% (95% confidence interval, 46 to
77), and the overall diagnostic accuracy was 66% (95%
confidence interval 53 to 78), and for pDLB the sensitiv-
ity was 89% (95% confidence interval 65 to 99), the spe-
cificity was 78% (95% confidence interval 62 to 89), and
the overall diagnostic accuracy was 81% (95% confidence
interval 69 to 90). The kappa coefficient for inter-rater
reliability at baseline assessments was 0.56.
Final clinical diagnosis
At final clinical assessment ten individuals were assigned
a clinical diagnosis of mixed AD+DLB, however only five
of these of these fulfilled neuropathological criteria for
mixed AD and DLB at post-mortem examination. Of the
22 neuropathologically diagnosed mixed AD+DLB cases,
the remaining seventeen were either given a clinical
diagnosis of AD (n = 7) or DLB (n = 10). Thus, the sen-
sitivity for mixed AD+DLB was only 23% (95% confi-
dence interval, 8 to 45) although the final specificity was
87% (95% confidence interval, 71 to 96), giving an over-
all diagnostic accuracy of 63% (95% confidence interval,
49 to 75). For the pAD cases final sensitivity was 68%
(95% confidence interval, 43 to 87) and the specificity
was 80% (95% confidence interval, 64 to 91) (overall ac-
curacy 76% (95% confidence interval, 63 to 86)) and for
pDLB it was 89% (95% confidence interval, 65 to 99)
and 71% (95% confidence interval, 45 to 89), respectively
(overall accuracy 76% (95% confidence interval, 63 to
86)). The kappa coefficient for inter-rater reliability for
final assessments was 0.59.
Individual symptoms
We also explored whether core, suggestive, and support-
ive symptoms of DLB might individually be useful to
clinically identify neuropathologically mixed AD+DLB
cases (see Table 2). As expected, three key LB symptoms,
complex visual hallucinations (VH), parkinsonism, and
RBD, had different frequencies between the groups. At
baseline, VH were less frequent in the mixed AD+DLB
cases compared to pDLB (P < 0.01), with no difference
between mixed AD+DLB and pAD. However, 50% of
mixed AD+DLB cases went on to develop VH during
the time course of the disease, which was significantly
higher than the pAD group (P < 0.05), although still
lower than the pDLB group (P < 0.01). At baseline, the
prevalence of RBD in neuropathologically mixed AD
+DLB cases was significantly lower than in pDLB
cases (P < 0.01) and was not different from the pAD
group (P = 0.46), which was similar when assessing
the groups for the emergence of RBD at any point
for the disease duration. Whilst parkinsonism oc-
curred in more people with mixed AD+DLB than in
those with pAD this was not statistically different.
Correcting for differences in age and dementia sever-
ity (MMSE score) did not affect this finding. Simi-
larly, cognitive fluctuations and neuroleptic sensitivity
were identified in similar proportions in mixed AD
+DLB cases and pAD cases, rendering these features
not useful for identifying mixed AD+DLB cases. None
of the other clinical features examined approached
significant differences (see Table 2).
Mixed cases
Of the 22 neuropathologically mixed AD+DLB cases,
eight had a baseline diagnosis of DLB and all of these
were regarded as having clinical DLB as their final diag-
nosis. Of the 14 who had AD as the baseline diagnosis,
seven subsequently had AD as their final diagnosis and
none of these had any identifiable LB symptoms at any
stage. The other seven did develop LB symptoms and
five of these were diagnosed as mixed AD+DLB while
the other two had a final diagnosis of DLB. In these lat-
ter two cases the gradual onset of degenerative dementia
was regarded as being due to DLB with LB symptoms
emerging later which enabled differentiation from AD.
Since these findings in the mixed group suggest that
the emergence of LB symptoms in the context of an AD
presentation should raise concerns about the presence of
LB disease, we compared these with the 19 pure AD
cases. Two of these 19 cases appeared also to later de-
velop VH. One had VH but importantly these were not
the complex VH in the DLB diagnostic criteria, but sim-
ple fleeting hallucinations, which often are associated
with poor eyesight. In the other case the patient had an
initial paranoid psychosis and developed parkinsonism
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on antipsychotics as well as a dementia. He also had an
abnormal 123I-FP-CIT SPECT dopaminergic imaging
scan which was thought clinically and at autopsy to be
due to brainstem cerebrovascular disease.
Discussion
We found that identification of DLB in the context of an
AD pattern of dementia is difficult but that complex vis-
ual hallucinations emerging later in the course of an
AD-type dementia suggest the presence of additional LB
disease pathology and, thus, mixed AD+DLB. This find-
ing is consistent with other studies, though importantly
these did not assess mixed cases [7–10]. In such circum-
stances a careful review of the diagnosis is merited, in-
cluding scrutiny for other symptoms of LB disease, and
antipsychotic medication should be avoided.
At baseline none of the mixed AD+DLB cases was
identified and even at final assessment, with full
Table 2 Lewy body symptoms by final neuropathological diagnosis
AD DLB Mixed AD+DLB
N = 19 N = 18 N = 22
Core and suggestive symptoms
Cognitive fluctuations ever 5 (26%) 9 (50%) 8 (36%) X = 2.23, df = 2, P = 0.33
Complex visual hallucinations at any time 3 (16%) 17 (94%) 11 (50%) X = 23.0, df = 2, P < 0.001
AD vs mixed, X = 5.31, df = 1, P = 0.02
DLB vs mixed, X = 9.30, df = 1, P < 0.01
Complex visual hallucinations at baseline 1 (5%) 12 (67%) 3 (14%) X = 20.86, df = 2, P < 0.01
AD vs mixed, X = 0.81, df = 1, P = 0.36
DLB vs mixed, X = 11.88, df = 1, P < 0.01
Complex visual hallucinations emerging later 2 (11%) 5 (28%) 8 (36%) X = 3.67, df = 2, P = 0.16
AD vs mixed, X = 3.69, df = 1, P = 0.055
DLB vs mixed, X = 0.33, df = 1, P = 0.564
Parkinsonism at any time 4 (21%) 12 (67%) 10 (45%) X = 7.83, df = 2, P = 0.02
AD vs mixed, X = 2.7, df = 1, P = 0.1
DLB vs mixed, X = 1.80, df = 1, P = 0.15
Parkinsonism at baseline 1 (5%) 8 (44%) 5 (23%) X = 7.86, df = 2, P = 0.02
AD vs mixed, X = 2.49, df = 1, P = 0.13
DLB vs mixed, X = 1.36, df = 1, P = 0.2
Parkinsonism emerging later 3 (16%) 4 (22%) 5 (23%) X = 0.36, df = 2, P = 0.84
RBD at any time 4 (21%) 12 (67%) 7 (32%) X = 7.83, df = 2, P = 0.02
AD vs mixed, X = 0.60, df = 1, P = 0.34
DLB vs mixed, X = 4.82, df = 1, P = 0.03
RBD at baseline 1 (5%) 6 (33%) 0 (0%) X = 11.69, df = 2, P < 0.01
AD vs mixed, X = 1.19, df = 1, P = 0.46
DLB vs mixed, X = 8.63, df = 1, P < 0.01
RBD emerging later 3 (16%) 6 (33%) 7 (32%) X = 1.83, df = 2, P = 0.4
Neuroleptic sensitivity at any time 3 (16%) 2 (11%) 3 (14%) X = 0.17, df = 2, P = 0.92
Exposed to use of neuroleptic 7 (37%) 9 (50%) 12 (55%) X = 1.35, df = 2, P = 0.51
Supportive symptoms
Falls at any time 7 (37%) 9 (50%) 11 (50%) X = 0.90, df = 2, P = 0.64
Other hallucinations at any time 1 (5%) 2 (11%) 5 (23%) X = 2.79, df = 2, P = 0.25
Delusions at any time 3 (16%) 7 (39%) 6 (27%) X = 2.79, df = 2, P = 0.25
Depression at any time 10 (53%) 9 (50%) 6 (27%) X = 3.30, df = 2, P = 0.19
Anxiety at any time 11 (58%) 9 (50%) 11 (50%) X = 0.32, df = 2, P = 0.85
Behavioural disturbance at any time 11 (58%) 8 (44%) 12 (55%) X = 0.73, df = 2, P = 0.70
AD Alzheimer’s disease, DLB dementia with Lewy bodies, RBD REM sleep behaviour disorder
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information on the evolution of the dementia, sensitivity
for detecting mixed AD+DLB was only 23%. Whilst we
found that the emergence of complex VH suggests the
presence of additional LB disease pathology and thus
mixed AD+DLB, no other DLB features proved useful
for identifying the presence of LB disease in the mixed
AD+DLB group in our study. Although parkinsonism
occurred more often in people who had mixed AD+DLB
this was not significantly greater than in AD, especially
later on in the illness where involvement of the substan-
tia nigra by tau pathology can cause parkinsonism [18].
However, the likelihood that parkinsonism in the context
of AD may be due to vascular causes at baseline (see the
end of the Results section) suggests that the presence of
parkinsonism due to Parkinson’s disease may be a useful
feature in identifying mixed AD+DLB if this can be reli-
ably identified. Similarly, RBD occurred more frequently
in mixed AD+DLB but not significantly more often than
in AD, especially later. It is surprising that several pAD
cases were identified as having RBD since this feature is
highly specific for LB disease and these are likely to have
been false positives, a finding that is probably related to
the difficulty in accurately identifying RBD in people
with more severe dementia where reliable clinical infor-
mation can be difficult to obtain. Overall, although RBD
and parkinsonism appeared to emerge in a few pAD
subjects, we are uncertain about the validity of these
symptoms and do not regard these in the context of
more advanced dementia as symptoms which would be
useful in supporting a DLB diagnosis. Although RBD is
highly specific to synucleinopathies it is difficult to reli-
ably identify it clinically, and parkinsonism is both diffi-
cult to identify clinically and may be due to other
pathologies, especially in more severe dementia.
One reason for the ‘failure’ to identify symptoms is
that the secondary pathology may not be present or ad-
vanced enough to be detected clinically at the early dis-
ease stage, since study subjects were only at the mild
dementia stage at baseline assessment. Alternatively, the
secondary pathology may be present but clinical assess-
ment alone is not sensitive enough to detect this and
biomarkers are necessary to do so. The absence of such
biomarker data is a limitation of our study, though one
which reflects the period in which cases were assessed.
There are two biomarkers validated against autopsy and
of proven diagnostic value in distinguishing DLB from
AD, dopaminergic imaging (specifically, FP-CIT SPECT
imaging [21]) and cardiac MIBG imaging [22]. None of
our subjects had MIBG since this is rarely used in the
United Kingdom, and only 16 had FP-CIT dopaminergic
scans. These cases were spread across the groups so that
the numbers were too low for meaningful comparison.
None of our patients had in vivo amyloid or tau imaging
and such assessments may make it possible in future to
identify AD in such mixed cases. Preliminary studies
investigating the tau ligand 18F-AV-1451 have indicated
increased binding of 18F-AV-1451 in the medial tem-
poral lobe can distinguish AD from probable DLB pa-
tients [23], and elevated cortical binding of 18F-AV-1451
to tau in DLB patients is associated with a decline in
cognition [24]. Furthermore, a quantitative post-mortem
pathological study has demonstrated a higher hyper-
phosphorylated tau burden in neuropathologically mixed
AD+DLB cases that had a clinical presentation of AD
compared with those with a DLB phenotype [20]. This
may indicate that these cases were originally following
the typical course of AD and developed LB pathology
later. Currently there are no synuclein-specific ligands
for in vivo imaging to identify LB disease. In the future
the use of such disease-specific imaging is likely to aid
differential diagnosis and disease stratification for clin-
ical trials, though currently the cost of such scans pro-
hibits widespread use and it is likely that criteria will be
needed to target such scans that will include identifying
clinical features such as complex visual hallucinations
that support the presence of LB disease.
When we focussed our analysis on the neuropathologi-
cally mixed AD+DLB cases this helped to further eluci-
date the difficulty in identification of LB disease in such
patients. About one-third (8 of 22) of the patients
appeared to begin their illness with clinical features con-
sistent with DLB. Such cases may have had co-AD path-
ology at this time or may subsequently have developed
AD pathology, but since no specific AD symptoms allow
its identification and no amyloid or tau biomarkers were
used in this study then such AD could not be identified
clinically. Another third (7 of 22) of the neuropathologi-
cally mixed AD+DLB cases had a typical AD presenta-
tion with no features suggestive of LB disease at all. The
final third of neuropathologically mixed AD+DLB cases
did have clear core and/or suggestive features of DLB,
but in these cases DLB-associated symptoms emerged
later. These findings are consistent with previous reports
that high-level Alzheimer’s pathology masks the add-
itional presence of characteristic LB symptoms and thus
the manifestation of LB disease [25]. Specifically, it is
not amyloid burden [26] but tau pathology burden that
obscures the presence of additional LB disease [27].
Clinico-pathological studies have endeavoured to de-
termine a clinical correlate that that will best predict the
clinical manifestation of DLB in the presence of co-
morbid AD. Comparison with these earlier studies is
limited by the different criteria being used such that, for
example, Lewy Body Variant (LBV) of AD was a broader
category including people with lower Braak stages than
in our study. Tiraboschi and colleagues found that visual
hallucinations were a highly specific feature for differen-
tiating DLB and AD in a neuropathologically validated
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cohort of AD and DLB [7], and we have now shown that
the development of such hallucinations in people with
an AD pattern of dementia indicates the presence of
DLB co-pathology, that is a mixed AD+DLB dementia.
An early study by Hansen et al. found visuospatial dys-
function, deficits in verbal fluency and attention, and
mild parkinsonian features to be more prominent in
patients with mixed AD+DLB pathology (termed by the
authors as Lewy body variant of AD) than in patients
showing AD pathology only [8]. However, this study was
limited by a relatively low sample size (nine mixed AD
+DLB), the use of ubiquitin immunolabelling rather than
α-synuclein for the detection of LB, and the absence of a
pure DLB group for comparison. Another study found a
higher frequency of visual hallucinations in mixed AD
+DLB cases compared to pure AD cases, but failed to
detect clinical differences between mixed AD+DLB and
pure DLB [9]. This study used α-synuclein immunohis-
tochemistry for some subjects but had limited ascertain-
ment of important clinical symptoms (e.g. visual
hallucinations or cognitive fluctuations) as these were
not specifically clinically assessed. They did find, how-
ever, that extrapyramidal symptoms were more frequent
in the mixed AD+DLB group but this was confounded
by the large proportion of patients (about two-thirds) on
antipsychotic drugs. A more recent study using α-
synuclein labelling in all cases compared autopsy-
confirmed mixed AD+DLB to classical AD and DLB
cases in patients with mild dementia at their first clinical
assessment [10]. This study included detailed neuro-
psychological assessment of patients but less thorough
clinical evaluation of characteristic DLB symptoms. It
found expected differences between classical AD and
classical DLB groups (worse visuospatial function and
better memory, as well as more extrapyramidal symp-
toms in DLB), but no differences were identified be-
tween the mixed AD+DLB patient group and the AD
group. In addition, it is important to note that neuro-
pathological assessment in the aforementioned studies
did not fulfil the full complement of consensus criteria
required for definite AD and DLB [4, 11–13, 19]. For
example, the study by Yoshizawa and colleagues [10]
contained cases with neurofibrillary tangle (NFT) Braak
stage IV in their AD and mixed AD+DLB groups whilst
their DLB group contained cases with NFT Braak stage
III, both of which would be categorised as having inter-
mediate AD neuropathologic change according to the
National Institute on Ageing—Alzheimer’s Association
criteria [19].
Another point to consider is the putative interactions
between multiple pathologies and the cumulative effect
this exerts on clinical dementia. Studies have demon-
strated that co-morbid pathologies are common in DLB
[28–31]; in particular, AD neuropathology has been
shown to associate with the timing and onset of demen-
tia in Lewy body diseases [16, 32]. Furthermore α-
synuclein has been shown to promote the aggregation of
both hyper-phosphorylated tau and β amyloid [33, 34],
which in the context of LB disease may enhance clinical
features associated with AD and mask the DLB
phenotype.
The prevalence of DLB varies depending on the type
of study and provenance of the patients, with brain bank
studies reporting DLB as constituting 12.5% of dementia,
hospital clinical studies indicating 7.2%, and community
studies reporting only 4.2% [35]. Whilst some of the dif-
ferences in these figures may result from selection bias,
other factors are also important. Some of these ‘missing’
DLB cases seem to reflect clinical experience and thus
expertise in diagnosis, with one study reporting variation
amongst secondary care settings in England ranging
from DLB constituting 2% of diagnosed dementia cases
to DLB making up 8% of dementia, a finding not
explainable by regional variation or service type [36].
However, in ADNI, subjects were thoroughly assessed
and diagnosed with either clinical dementia due to AD
or mild cognitive impairment (MCI) due to AD, and yet
at autopsy DLB was found in 45.5% of cases [37]. This
finding again demonstrates the high prevalence of un-
identified LB disease even in a thoroughly assessed AD
cohort. Others have reported that about 50% of AD
cases have significant LB pathology [38]. Approaching
this from the DLB diagnosis end, then perhaps 80% of
such cases have some AD co-pathology [3]. It is import-
ant to distinguish between mixed pathology [31], which
includes all different degrees of severity, and mixed
dementia, which only refers to cases which show the
full-blown pathology of two (or more) diseases such as
mixed AD+DLB [20, 39]. The number of ‘missed’ LB
cases depends on such definitions. However, our study
suggests that whilst many of these ‘missing LB cases’
cannot be identified, at least without specific biomarkers,
careful assessment for the presence of complex visual
hallucinations would help in identifying many such
cases.
This study benefited from having a thorough diagnos-
tic review by specialist doctors using all available clinical
and research records, and by the comprehensive neuro-
pathological assessments of all cases. Although our sub-
jects had detailed clinical and research records available,
recording the prospective development of symptoms in
their dementia, they were not all specifically prospect-
ively reviewed in a research study designed to identify
LB symptoms and so we cannot be sure that all relevant
symptoms were assessed at reviews. It should also be
noted that the mean time interval between final clinical
assessment and death in the neuropathologically mixed
AD+DLB group was just over 3 years, therefore giving
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time for progression of LB pathology and clinical expres-
sion of associated symptoms prior to neuropathological
assessment. Furthermore, we have discussed the absence
of biomarkers in this study above, reflecting the era in
which our brain bank subjects were assessed.
Conclusions
Careful evaluation for complex visual hallucinations can
help identify the presence of Lewy body disease in the
context of a dementia with a gradual decline typical of
AD. Such recognition of mixed AD+DLB may improve
clinical care by optimising DLB treatment in this con-
text. The recognition of multiple pathologies underlying
a dementia will become even more important when
disease-modifying treatments become available which
target specific pathologies, e.g. amyloid deposition. The
use of biomarkers appears likely to be necessary for such
disease identification.
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